THERAPY DOSSIER · th-42d2a5feeea9

IC486051 (selective phosphodiesterase type 4 inhibitor)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21355819 ↗2011Reported benefit

A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury.

RatSpinal cord injuryCompressionWistarintravenous0.5, 1.0 and 3.0 mg/kg2-60 h post-injury

Model: clip-compression thoracic spinal cord injury (moderately severe)

The PDE4 inhibitor (0.5-1.0 mg/kg) reduced oxidative stress and leukocyte infiltration and improved locomotion and neuropathic pain after SCI.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…